Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research
暂无分享,去创建一个
J. Szer | M. Tallman | K. Ballen | C. Nabhan | A. Keating | G. Schiller | M. Cairo | H. Lazarus | D. Weisdorf | R. Champlin | Vikas Gupta | C. Cutler | B. Camitta | J. Gajewski | D. Marks | M. Lill | W. Pérez | G. Socie | Gisela DaSilva
[1] N. Novitzky,et al. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] M. Tallman,et al. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. , 2011, Blood.
[3] M. Labopin,et al. Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. , 2010, Blood.
[4] B. Williams,et al. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. , 2010, Cytotherapy.
[5] J. Dipersio,et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. , 2010, Blood.
[6] R. Wäsch,et al. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] M. Maris,et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Ritz,et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] F. M. Stewart,et al. Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission , 2010, Leukemia.
[10] J. Sierra,et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Labopin,et al. Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Labopin,et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] John P Klein,et al. Analyzing survival curves at a fixed point in time , 2007, Statistics in medicine.
[14] M. Minden,et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] P. Sonneveld,et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research , 2005, British journal of haematology.
[16] Jun Yan. Survival Analysis: Techniques for Censored and Truncated Data , 2004 .
[17] R. Tsang,et al. Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia , 2004, Bone Marrow Transplantation.
[18] J. Bourhis,et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.
[19] C. Linker. Autologous stem cell transplantation for acute myeloid leukemia , 2003, Bone Marrow Transplantation.
[20] J. Finke,et al. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Goldstone,et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.
[22] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[23] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[24] A. Hagenbeek,et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? , 1999, Bone Marrow Transplantation.
[25] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[26] H. Rugo,et al. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report , 1998, Bone Marrow Transplantation.
[27] F. Mandelli,et al. The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA , 1998, British journal of haematology.
[28] Keith Wheatley,et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.
[29] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[30] D. Lin,et al. Non-parametric inference for cumulative incidence functions in competing risks studies. , 1997, Statistics in medicine.
[31] P. Cony-Makhoul,et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. , 1996, Leukemia.
[32] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[33] H. Rugo,et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] D.,et al. Regression Models and Life-Tables , 2022 .